No retatrutide and Ozempic are different medications and may be used in different clinical situations
In a recent review published in the journal Cell Metabolism , a group of authors explored how Glucagon-Like Peptide-1 receptor (GLP-1R) agonism shapes the neurovascular unit (NVU), potentially linking metabolic health improvements to enhanced brain health
In Phase 3 clinical trials, retatrutide has been studied as a once-weekly injection, starting at 2mg once weekly and increasing gradually every four weeks
Alternative medication classes should be considered if GLP-1 therapy proves intolerable: SGLT2 inhibitors (such as dapagliflozin, empagliflozin) for type 2 diabetes, which work via a completely different mechanism and rarely cause gastrointestinal side effects DPP-4 inhibitors (such as sitagliptin, linagliptin), which enhance endogenous GLP-1 activity more gently Metformin remains first-line for type 2 diabetes, though it can also cause gastrointestinal side effects Orlistat for weight management, though this also has gastrointestinal side effects of a different nature For weight management specifically, NICE recommends a comprehensive approach including dietary modification, increased physical activity, and behavioural interventions, with or without pharmacotherapy
This drug is unique because it can activate three different hormone receptors in the body that control appetite and metabolism
Switching to a different GLP-1 medication, reducing the dose, or considering alternative drug classes may be appropriate if symptoms remain intolerable
